OncLive® On Air S15 Ep42: Long-Term Epcoritamab Data Show Durable Responses and Confirmed Safety in LBCL: With Tycel Phillips, MD
Jan 30, 2026
Tycel Phillips, associate professor in lymphoma and transplant at City of Hope, shares updates on long-term epcoritamab data. He discusses durability of complete responses beyond four years. He reviews safety with extended follow-up and the role of epcoritamab as a third-line option. He also highlights promising combinations pairing antibody drug conjugates with bispecifics.
AI Snips
Chapters
Transcript
Episode notes
Epcoritamab Dosing And Response Rates
- EPCORE NHL-1 established a step-up dosing schedule and maintenance frequency for epcoritamab leading to regulatory approvals in LBCL and follicular lymphoma.
- About 39–40% of patients achieved complete responses, which drive the longest durations of benefit.
Durable Complete Responses Over Years
- Long-term follow-up showed a median duration of complete response of ~37.7 months with some patients remaining in CR beyond 4 years.
- Only seven patients progressed after the first year, suggesting durable remissions that may approach cure in some cases.
Monitor Infections, Weigh Discontinuation Reasons
- Continue monitoring for infections but recognize no new major safety signals emerged with long-term epcoritamab exposure.
- Consider treatment discontinuation for patient preference or intolerance rather than defaulting to adverse-event concerns.